-
Celltrion Announces U.S. FDA Approval Of Additional Presentation Of STEQEYMA® (Ustekinumab-Stba), Expanding Dosing Options For Pediatric Patients
16 Jun 2025 00:47 GMT
… treatment continuity for patients.
In December 2024, the FDA … Our global pharmaceutical portfolio addresses … drugs to push the boundaries of scientific innovation and deliver quality medicines … rituximab-abbs), HERZUMA® (trastuzumab-pkrb), VEGZELMA® (bevacizumab …
-
Hope S. Rugo, MD, Discusses Retreatment for HER2+ Breast Cancer With Trastuzumab Deruxtecan After ILD
15 Jun 2025 20:37 GMT
… remain about the drug’s association with … professor, Department of Medical Oncology and Therapeutics Research … trials, but it has not disappeared: In the 2019 DESTINY-Breast01 trial … et al. Treatment rechallenge after trastuzumab-deruxtecan–related interstitial …
-
How Precision Medicine Is Changing the Fight Against Cancer
13 Jun 2025 23:28 GMT
… antibodies have reshaped treatment outcomes. Trastuzumab (Herceptin) effectively … groundbreaking clinical trial showed that patients … trials.
What are the challenges of precision medicine?
Precision medicine … in drug development and treatment delivery systems …
-
Research Progress of PROTAC-Degraded CDKs in the Treatment of Breast Cancer
13 Jun 2025 17:47 GMT
… first PROTAC to enter clinical trials, marking an important step in … tumor research, drug development and precision medicine, and bring more treatment options and … drives breast tumor initiation and trastuzumab resistance via WNT and IRS1 …
-
Antibody-Drug Conjugate Efficacy and Safety in HER2-Mutated NSCLC
13 Jun 2025 14:10 GMT
Panelists discuss how antibody drug conjugates like trastuzumab deruxtecan work as “Trojan horses … cells, providing effective second-line treatment for patients with HER2-mutated …
-
Recognizing and Treating Interstitial Lung Disease Associated With Trastuzumab Deruxtecan
13 Jun 2025 14:10 GMT
Panelists discuss how interstitial lung disease represents a critical and potentially cryptic toxicity occurring in 10% to 15% of patients receiving HER2 antibody-drug conjugates, requiring vigilant monitoring, prompt recognition of subtle symptoms like …
-
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent
13 Jun 2025 11:01 GMT
… U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® … two years of treatment or a medical condition that … FDA-approved test.
Gastric Cancer
KEYTRUDA, in combination with trastuzumab … ; the impact of pharmaceutical industry regulation and health …
-
Celltrion biosimilars gain dominance in Japanese drug market
13 Jun 2025 05:43 GMT
… breast and gastric cancer treatment Herzuma (ingredient: trastuzumab) and metastatic colorectal … unique characteristics of the Japanese pharmaceutical system.
Notably, Celltrion … drugs because they retain savings generated by using lower-priced medicines …
-
Celltrion Solidifies Presence in Japan’s Oncology Drug Market
13 Jun 2025 03:44 GMT
… that its biosimilar oncology drugs, Herzuma (generic name: trastuzumab) and Vegzelma (generic … the characteristics of the Japanese pharmaceutical market and supportive policies for … Japanese market for autoimmune disease treatments. Celltrion's infliximab …
-
Celltrion’s Cancer Drug Herzuma Achieves 75% Market Share in Japan
13 Jun 2025 02:14 GMT
… as of April.
According to pharmaceutical market research firm IQVIA and … ’s breast and gastric cancer treatment Herceptin (trastuzumab).
During the same period … the characteristics of the Japanese pharmaceutical market, as well as biosimilar …
About
© 1995-2025